Curasight doses first patient in Phase 1 study for brain tumor treatment

Published: 12/18/2025 5:28:17 PM

This is a news from the Finwire news agency Disclaimer

Finwire about Curasight A/S: Curasight doses first patient in Phase 1 study for brain tumor treatment

The research company Curasight has dosed the first patient in a Phase 1 study with uTREAT for aggressive brain tumor. This is stated in a press release.The study concerns patients with glioblastoma.